Page 78 - Read Online

Page 4 of 4 Candelaresi et al. Vessel Plus 2018;2:11 I http://dx.doi.org/10.20517/2574-1209.2018.09

DECLARATIONS
Authors’ contributions
Conceived the idea of the manuscript and wrote the first draft: Candelaresi P
Searched for the literature and critically revised the manuscript: Casorio MC
Approved the final version: both authors

Financial support and sponsorship
None.

Conflicts of interest
The authors confirm that this case content has no conflicts of interest.

Patient consent
The authors declare that a written informed consent has been obtained from the patient to publish
anonymous information.

Ethics approval
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology,
and outstanding questions. Lancet Neurol 2015;14:914-25.
2. Terwiel E, Hanrahan R, Lueck C, D’Rozario J. Reversible posterior encephalopathy syndrome associated with bortezomib. Intern Med
J 2010;40:69-71.
3. Kelly K, Kalachand R, Murphy P. Bortezomib-induced reversible posterior leucoencephalopathy syndrome. Br J Haematol
2008;141:566.
4. Kager LM, Kersten MJ, Kloppenborg RP, Van Oers R, Van den Born BJ. Reversible posterior leucoencephalopathy syndrome associated
with bortezomib in a patient with relapsed multiple myeloma. BMJ Case Rep 2009;2009:bcr06.2009.1926.
5. Oshikawa G, Kojima A, Doki N, Kobayashi T, Kakihana K, Tsuda H, Endo I, Kamata N, Ohashi K, Sakamaki H. Bortezomib-induced
posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma. Intern Med 2013;52:111-4.
6. Nixon NA, Parhar K. Posterior reversible encephalopathy syndrome resulting from repeat bortezomib usage. BMJ Case Rep
2014;2014:bcr2014204592.
7. Ho CH, Lo CP, Tu MC. Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features. Intern Med
2014;53:1853-7.
8. Hsiao SC, Wang MC, Chang H, Pei SN. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed
myeloma. Ann Pharmacother 2010;44:587-9.
9. Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, Coriat R, Goldwasser F. Posterior reversible encephalopathy
syndrome induced by anti-VEGF agents. Target Oncol 2011;6:253-8.
10. Najera JE, Sudhakar T, Bashir Q, Shah N, Champlin RE, Qazilbash MH, Giralt S, Hosing C, Popat UR, Ciurea SO. Neurotoxicity after
high-dose melphalan. J Clin Oncol 2012;30 suppl 15:abstr6546.